Form 4 for ALKS Alkermes plc.
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-08 · accession 0001127602-23-029515 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-12 | 2023-12-08 | ALKS | LAURENCIN CATO T | Dir | F - Tax | $25.86 | -1,000 | 15.2K | -6% | -$25.9K |
| D | 2023-12-12 | 2023-12-08 | ALKS | LAURENCIN CATO T | Dir | M - OptEx | — | +4,163 | 16.2K | +35% | — |
| DM | 2023-12-12 | 2023-11-17 | ALKS | LAURENCIN CATO T | Dir | J - Other | $26.45 | +1,301 | 13.0K | +11% | +$34.4K |
| D | 2023-12-12 | 2023-12-08 | ALKS | LAURENCIN CATO T | Dir | M - OptEx | — | -4,163 | 4,163 | -50% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2023-12-08 | F | D | 1,000 | $25.86 | 15,169 | D | — | — | |
| 2 | Common | Ordinary Shares | 2023-12-08 | M | A | 4,163 | — | 16,169 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. |
| 3 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 163 | — | 8,326 | D | — · — to — | 163 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F8) Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. |
| 4 | Derivative | Restricted Stock Unit Award | 2023-11-17 | J | A | 119 | — | 6,104 | D | — · 2024-06-29 to — | 119 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F7) Shares subject to the restricted stock unit award vest in full on 6/29/2024. |
| 5 | Derivative | Non Qualified Stock Option (Right to Buy) | 2023-11-17 | J | A | 112 | $22.52 | 5,712 | D | $22.52 · — to 2031-12-08 | 112 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F3) This award is fully vested in accordance with its terms. |
| 6 | Derivative | Non Qualified Stock Option (Right to Buy) | 2023-11-17 | J | A | 422 | $22.52 | 21,523 | D | $22.52 · — to 2031-12-08 | 422 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F4) Shares subject to the stock option award vest in three equal annual installments commencing on 12/8/2022. |
| 7 | Derivative | Non Qualified Stock Option (Right to Buy) | 2023-11-17 | J | A | 231 | $30.86 | 11,785 | D | $30.86 · — to 2032-07-07 | 231 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F5) These options are fully vested in accordance with their terms. |
| 8 | Derivative | Restricted Stock Unit Award | 2023-12-08 | M | D | 4,163 | — | 4,163 | D | — · — to — | 4,163 Ordinary Shares | (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F8) Shares subject to the restricted stock unit award vest in three annual installments commencing on 12/8/2022. |
| 9 | Derivative | Non Qualified Stock Option (Right to Buy) | 2023-11-17 | J | A | 254 | $30.72 | 12,986 | D | $30.72 · 2024-06-29 to 2033-06-29 | 254 Ordinary Shares | (F2) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F6) Shares subject to the stock option award vest and become exercisable in full on 6/29/2024. |